Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023
- Amicus Therapeutics to present 104-week efficacy and safety data of cipaglucosidase alfa + miglustat in late-onset Pompe disease.
- Switching treatment to cipaglucosidase alfa plus miglustat positively affects motor function and quality of life in late-onset Pompe disease.
- None.
PRINCETON, N.J., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and four posters highlighting its development program for Pompe disease will be included at the 28th Annual Congress of the World Muscle Society (WMS), being held October 3-7, 2023 in Charleston, SC.
Oral Presentation:
Abstract Title: 104-week efficacy and safety of cipaglucosidase alfa + miglustat in patients with late-onset Pompe disease previously treated with alglucosidase alfa (Oral #O21)
- Presenter: Tahseen Mozaffar, MD, Department of Neurology, University of California, Irvine, CA, U.S.A.
- Date and time: Saturday, October 7, 7:45-8:45 a.m. E.T.
- Location: PAC, Charleston Area Convention Center
Poster Sessions:
Abstract Title: Switching treatment to cipaglucosidase alfa plus miglustat positively affects motor function and quality of life in patients with late-onset Pompe disease (Poster #P371)
- Presenter: Kristl G. Claeys, MD, PhD, University Hospitals Leuven, Leuven, Belgium
- Poster Session 3: Friday, October 6, 2:00-3:00 p.m. E.T.
- Location: Ballroom A-C, Charleston Area Convention Center
Abstract Title: Effect size analysis of cipaglucosidase alfa plus miglustat versus alglucosidase alfa in ERT-experienced adults with late-onset Pompe disease in PROPEL (Poster #P373)
- Presenter: Jordi Díaz-Manera, MD, PhD, John Walton Muscular Dystrophy Research Centre, Newcastle upon Tyne, U.K.
- Poster Session 3: Friday, October 6, 2:00-3:00 p.m. E.T.
- Location: Ballroom A-C, Charleston Area Convention Center
Abstract Title: Safety of home administration of cipaglucosidase alfa plus miglustat in late-onset Pompe disease: results from multiple clinical trials (Poster #P372)
- Presenter: Barry J. Byrne, MD, PhD, University of Florida, Gainesville, FL, U.S.A.
- Poster Session 3: Friday, October 6, 2:00-3:00 p.m. E.T.
- Location: Ballroom A-C, Charleston Area Convention Center
Abstract Title: Disease burden, treatment patterns and healthcare resource utilization associated with Pompe disease in Sweden: a real-world evidence study (ePoster #VP369)
- Presenter: Christopher Lindberg, MD, Neuromuscular Centre, Sahlgrenska University Hospital, Gothenburg, Sweden
- Poster Session 3: Friday, October 6, 2:00-3:00 p.m. E.T.
- Location: Virtual Platform
For more information on the World Muscle Society 2023, please visit wms2023.com.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on Twitter and LinkedIn.
CONTACTS:
Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Communications
dmoore@amicusrx.com
(609) 662-5079
FOLD–G
